Table 2.

Distribution of DNA methylation factors in responders and non-responders by trial arm

	Cidofovir ($N=$ 65)						Imiquimod ($N=$ 67)
	No response ($N=$ 30)		Response ($N=$ 35)		Rank sum result	(i/m) Q${}^{**}$	No response ($N=$ 27)		Response ($N=$ 40)		Rank sum result	(i/m) Q${}^{**}$
HPV 16	n (%)		n (%)				n (%)		n (%)
Negative	5	(38.5)	8	(61.5)	${\lambda }^2=$ 0.387	0.071	3	(23.1)	10	(76.9)	${\lambda }^2=$ 1.988	0.029
Positive	25	(48.1)	27	(51.9)	$p=$ 0.534		24	(44.4)	30	(55.6)	$p=$ 0.159
Any HPV	n (%)		n (%)				n (%)		n (%)
Negative	2	(50.0)	2	(50.0)	${\lambda }^2=$ 0.025	0.1	0	(0.0)	4	(100.0)	${\lambda }^2=$ 2.871	0.021
Positive	28	(45.9)	33	(54.1)	$p=$ 0.873		26	(42.9)	36	(57.1)	$p=$ 0.090
Methylation	Median (IQR)${}^{\mathrm{*}}$		Median (IQR)${}^{\mathrm{*}}$				Median (IQR)${}^{\mathrm{*}}$		Median (IQR)${}^{\mathrm{*}}$
HPV16 $E2$	2.7	(0–3.7)	2.7	(0–15.7)	$z=-$0.811 $p=$ 0.418	0.057	3.2	(0–81.6)	2.2	(0–6.6)	$z=$ 1.320 $p=$ 0.187	0.043
S5	9.8	(7.4–16.3)	13.4	(6.7–18.2)	$z=-$0.868 $p=$ 0.385	0.050	13.4	(8.9–17.7)	2.2	(9.3–13.4)	$z=$ 2.339 $p=$ 0.019	0.014
EPB41L3	5.1	(3.4–11.2)	5.7	(3.5–13.7)	$z=-$0.632 $p=$ 0.528	0.064	4.8	(2.7–10.4)	4.7	(3.2–5.9)	$z=$ 0.256 $p=$ 0.798	0.093
HPV 16 $L1$	21.2	(0–85.6)	28.8	(0–92.1)	$z=-$0.307 $p=$ 0.759	0.079	36.0	(14.4–93.4)	12.2	(0–55.7)	$z=$ 2.714$p=$ 0.006	0.007
HPV 16 $L2$	8.1	(0–10.6)	8.1	(0–62.2)	$z=$ 0.273 $p=$ 0.785	0.086	8.9	(0–67.8)	3.2	(0–15.0)	$z=$ 1.340 $p=$ 0.180	0.036

${}^{*}$Missing results treated as “0”. ${}^{**}$Critical value to control for false discovery rate – p must be below this to be counted as significant.